Search results
Results from the WOW.Com Content Network
Body fat redistribution (BFR) syndrome, sometimes called fat derangement, is a medical condition characterized by fat loss (or occasionally fat gain), often in the cheeks or face. BFR most often occurs in HIV / AIDS patients undergoing antiretroviral therapy.
Fat redistribution and accumulation was more commonly seen in individuals receiving antiretroviral therapy, particularly older antiretrovirals, for the treatment of HIV. [36] No significant changes in fat redistribution or change in fat had been noted when used as a pre-exposure prophylaxis.
3. Sleep Deprivation. There is a link between sleep loss and weight gain. Research shows that people who routinely don’t get enough sleep tend to eat higher-calorie and higher-fat diets.. Not ...
The World Health Organization (WHO) issued consultative recommendations regarding nutrient requirements in HIV/AIDS. [6] A generally healthy diet was promoted. For HIV-infected adults, the WHO recommended micronutrient intake comes from a good diet at RDA levels; higher intake of vitamin A, zinc, and iron can produce adverse effects in HIV positive adults, and these were not recommended unless ...
Anti-obesity medication or weight loss medications are pharmacological agents that reduce or control excess body fat. These medications alter one of the fundamental processes of the human body , weight regulation, by: reducing appetite and consequently energy intake , increasing energy expenditure , redirecting nutrients from adipose to lean ...
Strong sales of medicines for HIV, the virus that causes AIDS, were one of the drivers behind the company's performance last year, generating 6.44 billion pounds ($8.13 billion) in annual sales.
Heterosexual men or women who do not regularly use condoms during sex with partners of unknown HIV status who are substantial risk; Injection of drugs in the last six months with sharing of equipment; Serodiscordant heterosexual and homosexual partners, where one partner is HIV-positive and the other HIV-negative
It works by inhibiting the enzyme reverse transcriptase that HIV uses to make DNA and therefore decreases replication of the virus. [6] Zidovudine was first described in 1964. [7] It was resynthesized from a public-domain formula by Burroughs Wellcome. [8] It was approved in the United States in 1987 and was the first treatment for HIV.